Lonza Invests to Expand Mid-Scale Small Molecule Production Capacity, HPAPI Production at Nansha, China, Facility
Pharma and biotech innovators have a growing need for effective, seamless ways to move small molecule compounds from early stage to commercial manufacturing in line with global quality standards.
To help pharma and biotech companies scale up production rapidly and effectively, Swiss CDMO Lonza recently announced an investment of CHF 20 million to bring flexible, mid-scale manufacturing capabilities to its API Development and Manufacturing facility in Nansha, China.
- The expansion will include six 1,000L small molecule reactors, four 1,500L vessels and isolation equipment to provide mid-scale capacity to bridge between early-phase and late-phase production
- Also included in the expansion are three 1000L GMP trains with 12m3 of reactor volume
- The first buildout, expected to start its operations in Q3 2023, will be a dedicated manufacturing line for highly potent APIs (HPAPI) and antibody-drug conjugate payload molecules for oncology treatment
- The expanded capabilities address increasing interest from pharma and biotech companies in China as a site for development and manufacturing of global products with greater access to clinical trials
- Once completed, the expansion should create about 70 new positions, bringing the total number of staff employed at the Nansha site to roughly 320
- The new investments will include three 1,000L GMP trains with an overall 12m3 of reactor volume, including new development and GMP laboratories with capabilities to manufacture small scale batches of highly potent APIs (HPAPIs)
- Expanded capacity in Nansha will allow for mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
- Capabilities add to Lonza’s integrated global manufacturing network, which maintains rigorous quality and regulatory standards around the world
Jan Vertommen, Senior Director, Commercial Development, Lonza, said “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. These companies need cost-effective, seamless ways to move small molecule compounds from early-phase to commercial according to global quality and regulatory standards, and these expanded facilities at our Nansha site are designed to help them to do so.”
Gordon Bates, President, Division Small Molecules, Lonza, added “Global pharma and biotech companies are increasingly looking to China, both for development and manufacturing of global products and in some cases for greater access to clinical trials conducted in China. With these expanded capabilities at our Nansha site, we aim to support the next generation of innovative and life-saving drug development with our customers around the world.”
Visit https://pharma.lonza.com/about/locations/nansha-china for more information.
Total Page Views: 1118
